Impact of Brexit on Regulatory Framework

The most important piece of UK legislation that would need to be repealed is the European Communities Act 1972 (ECA), which provides for the supremacy of EU law. Repealing the ECA will bring an end to the constitutional relationship that exists between EU and UK law. Moreover, the vast amounts of secondary legislation that have been passed with the objective and justification of implementing EU law would have to be considered by the Government. EU Regulations rely on the principle of direct applicability, which means that unlike EU Directives, they are directly implemented into UK law without the need for legislation from the UK Parliament. In this light, Regulations are more powerful legislative tools for the EU because of their immediate applicability. The status of existing Regulations will be addressed in the Great Repeal Bill, although as noted above, in many cases amendments will likely be needed to take into account the UK’s new relationship with the EU. The Court of Justice of the European Union (CJEU) situated in Luxembourg is the final arbiter on questions of the interpretation of EU law. In her first speech setting out the UK Government’s priorities for Brexit on 17 January 2017, the Prime Minister restated her position that the UK is not prepared to continue to be subject to the jurisdiction of the CJEU.

 

  • Brexit effects on Pharmacovigilance and Protocols
  • Brexit effects on Clinical Trials
  • Exclusions and inclusions in regulatory affairs
  • Pharmacoeconomic aspects of Brexit

Related Conference of Impact of Brexit on Regulatory Framework

September 28-29, 2018

11th World Congress on Pharmaceutical Sciences

| Montreal, Canada
October 24-25, 2018

13th International Conference on Biopharma and Biotherapeutics

Boston, Massachusetts, USA
November 05-07, 2018

18th Annual Pharma Middle East Congress

Abu Dhabi, UAE
November 14-15, 2018

13th World Congress on Pharmacology and Toxicology

Melbourne, Australia
November 15-16, 2018

9th Global Experts Meeting on Neuropharmacology

Berlin, Germany
Feb 28-March 01, 2019

International Conference on Bio-Pharmaceuticals

Osaka, Japan
April 22-23, 2019

6th World Congress on Drug Discovery & Toxicology

Abu Dhabi, UAE
March 25-26, 2019

World Congress on Pharmaceutical Biotechnology & Bioengineering

Orlando, Florida, USA
March 27-28, 2019

5th International Conference on Clinical Pharmacy and
Health Care

San Antonio, Texas, USA
April 04-06, 2019

4th Annual Congress on Nanomedicine and Drug Delivery

Auckland, NewZealand
April 15-16, 2019

12th European Biosimilars Congress

Berlin, Germany
April 17-18, 2019

11th World Congress on Pharmacology & Therapeutics

Montreal, Canada
April 17-18, 2019

Annual Neurochemistry and Neuropharmacology Congress

| Montreal, Canada
April 17-18, 2019

International Conference on Global Analytica

Osaka, Japan
May 20-21, 2019

21st Annual European Pharma Congress

Zurich, Switzerland
April 22-24, 2019

20th Asia-Pacific Pharma Congress

Tokyo, Japan
March 22-23, 2019

5th International Conference on Antibiotics

Orlando, USA
June 17-18, 2019

7 th European Biopharma Congress

Stockholm, Sweden
June 17-18, 2019

14th World Congress on Pharmacology and Drug Safety

Lisbon, Portugal
June 27-29, 2019

18th Annual Congress on Pharmaceutics & Drug Delivery Systems

Amsterdam, Netherlands
August 19-20, 2019

24th World Congress on Pharmacology

Vienna, Austria
September 11-13, 2019

8th International Conference on Clinical Trials

| Orlando, Florida, USA

Impact of Brexit on Regulatory Framework Conference Speakers

Recommended Sessions

Related Journals

Are you interested in